1: (ROOT (SINV (NP (NP (NP (DT The) (NNP Next) (NNP Frontier)) (PP (IN of) (NP (NNP Mitochondrial) (NNP Medical) (NNPS Applications)))) (VP (VBG Becoming) (NP (NP (DT the) (NN world) (POS 's)) (ADJP (ADJP (ADJP (RBS most) (JJ advanced)) (CC and) (ADJP (JJS largest))) (JJ professional)) (NML (JJ mitochondrial) (NN technology) (CC and) (NN manufacturing)) (NN leader)))) (VP (VBZ is)) (NP (NP (DT the) (NN vision)) (PP (IN of) (NP (NP (JJS most) (NN biotech) (NNS companies)) (PP (IN in) (NP (NP (DT the) (NN field)) (PP (IN of) (NP (NP (NNS mitochondria) (CC and) (JJ mitochondrial) (NN research)) (, ,) (CC and) (NP (JJ preventive) (NN medicine))))))))) (. .)))
2: (ROOT (S (S (NP (JJ Mitochondrial) (NNS disorders)) (VP (VBP are) (ADJP (ADJP (JJ mult) (HYPH -) (JJ systemic)) (CC and) (ADJP (JJ commonplace))))) (, ,) (CC and) (S (NP (PRP it)) (VP (VBZ belongs) (PP (IN to) (NP (NP (DT a) (JJ prevalent) (NN category)) (PP (IN of) (NP (VBN inherited) (JJ neurometabolic) (NNS diseases))))))) (. .)))
3: (ROOT (S (S (NP (JJ Such) (NNS diseases)) (VP (VBP are) (ADJP (ADVP (RB clinically) (, ,) (RB genetically) (CC and) (RB chemically)) (JJ heterogeneous)) (SBAR (RB so) (IN that) (S (NP (NN recognition) (CC and) (NN diagnosis)) (VP (VBP are) (ADVP (RB frequently)) (ADJP (JJ difficult))))))) (, ,) (CC but) (S (ADVP (RB thankfully)) (, ,) (PP (IN for) (NP (NP (JJS most)) (PP (IN of) (NP (DT the) (NNS patients))))) (, ,) (NP (NP (JJ recent) (NNS advances)) (PP (IN in) (NP (NML (JJ nex) (HYPH -) (NN generation)) (NN sequencing) (NN technology)))) (VP (VBZ has) (VP (VBN led) (PP (IN to) (NP (NP (JJ great) (NNS improvements)) (PP (IN in) (NP (JJ genetic) (NN diagnosis)))))))) (. .)))
4: (ROOT (S (PP (IN Due) (IN to) (NP (NP (NP (DT the) (NN variability)) (IN of) (NP (NNS features) (CC and) (NN nature))) (PP (IN of) (NP (DT the) (ADJP (JJ biochemical) (CC or) (JJ genetic)) (NNS defects))))) (, ,) (NP (NP (JJ early) (NN referral)) (PP (IN to) (NP (DT a) (JJ specialized) (NN center)))) (VP (VBZ is) (VP (VBN recommended) (SBAR (IN because) (S (NP (NML (JJ improved) (NML (NNS diagnostics))) (CC and) (NML (NNP NGS) (NN use))) (VP (VBP have) (VP (VBN enabled) (NP (NP (NP (DT an) (JJR earlier) (NN diagnosis)) (PP (IN for) (NP (JJ many)))) (, ,) (CONJP (CONJP (RB as) (RB well) (IN as)) (ADVP (RB sometimes))) (NP (NP (JJ early) (NN instigation)) (PP (IN of) (NP (NP (JJ effective) (NN therapy)) (CC and) (NP (NN precision) (NN medicine)))))))))))) (. .)))
5: (ROOT (S (S (NP (EX There)) (VP (VBZ is) (ADVP (RB currently)) (NP (NP (DT no) (NN cure)) (ADJP (JJ available) (PP (IN for) (NP (NP (DT the) (NN majority)) (PP (IN of) (NP (JJ such) (NNS conditions))))))))) (, ,) (CC and) (S (NP (JJ clinical) (NN care)) (VP (VBZ is) (ADVP (RB largely)) (VP (VBN restricted) (PP (IN to) (S (VP (VP (VBG negating) (NP (NP (DT the) (NNS complications)) (PP (IN of) (NP (DT these) (NNS diseases))))) (CC or) (VP (VBG assisting) (NP (NN prevention)) (PP (IN through) (NP (NP (JJ prenatal) (NN testing)) (, ,) (NP (NML (JJ mitochondrial) (NN donation)) (NN therapy)) (CC and) (NP (JJ preimplantation) (JJ genetic) (NN diagnosis))))))))))) (. .)))
6: (ROOT (S (PP (IN As) (ADJP (JJ such))) (, ,) (NP (NP (DT the) (NML (JJ limited) (NNS options))) (CC and) (NML (NML (NN lack)) (PP (IN of) (NP (JJ curative) (NN treatment) (NNS options))))) (VP (VBP have) (VP (VBN created) (NP (NP (NP (JJR more) (NNS opportunities) (CC and) (NNS investments)) (PP (IN into) (NP (JJ individual) (NN therapy) (NNS trials)))) (, ,) (VP (VBN focused) (PP (IN on) (S (VP (VP (VBG optimizing) (NP (JJ oxidative) (NN phosphorylation))) (CC and) (VP (VBG improving) (NP (NN antioxidant) (NN capacity)))))))))) (. .)))
7: (ROOT (S (PP (IN In) (NP (NN essence))) (, ,) (NP (NP (DT a) (NN combination)) (PP (PP (IN of) (NP (NNS vitamins))) (, ,) (PP (VBG including) (NP (NP (NN coenzyme) (CD Q10)) (, ,) (NP (NN thiamine)) (CC and) (NP (NN riboflavin))))) (PP (IN in) (NP (NP (NN addition)) (PP (IN to) (NP (NP (JJ other) (JJ regenerative) (JJ medicinal) (NNS approaches)) (PP (IN in) (NP (DT the) (NML (NML (NNS telomeres)) (, ,) (NML (NN stem) (NN cell)) (CC and) (NP (NN senescent) (NNS cells)))))))))) (VP (VBZ is) (VP (VBN recommended))) (. .)))
8: (ROOT (S (PP (IN As) (PP (IN of) (NP (NNP February) (CD 2020)))) (, ,) (NP (QP (JJR more) (IN than) (CD 250)) (NNS trials)) (VP (VBP are) (ADJP (VBG ongoing)) (ADVP (RB worldwide)) (S (VP (VBG investigating) (NP (JJ potential) (JJ therapeutic) (NNS approaches))))) (. .)))
9: (ROOT (NP (NP (NNP Mitochondrion) (NNP Application)) (NP (NP (NNP Biomedicine)) (PP (IN In))) (. ..)))
10: (ROOT (S (VP (VP (VBZ is) (NP (NP (CD one) (JJ such) (NN company)) (VP (VBG conducting) (NP (JJ such) (NNS trials))))) (CC and) (VP (VBZ aims) (S (VP (TO to) (VP (VB fulfil) (NP (DT this) (NN mission)) (PP (IN by) (S (VP (VBG forming) (NP (DT a) (JJ strong) (JJ competitive) (NN team)) (PP (IN with) (NP (PRP$ our) (NML (JJ medical) (NNS institutions)) (CC and) (NML (NNS customers)))) (, ,) (PP (IN as) (NP (NP (DT a) (ADJP (NML (JJ lon) (HYPH -) (NN term)) (CC and) (JJ trusted)) (NML (NN technology) (CC and) (NN capacity)) (NN provider)) (PP (IN in) (NP (DT the) (JJ global) (SYM mitochondrial/) (NN cell) (NN therapy) (NN industry))))))))))))) (. .)))
11: (ROOT (S (NP (NNS Scientists)) (VP (VBP are) (VP (VBG working) (NP (NN night) (CC and) (NN day)) (, ,) (S (VP (VBG racing) (S (VP (TO to) (VP (VB find) (NP (NP (DT a) (NN cure)) (PP (IN for) (NP (DT the) (JJ novel) (NN coronavirus))))))))))) (. .)))
12: (ROOT (S (NP (NP (DT An) (NML (NNP Eas) (HYPH -) (NN meet) (HYPH -) (NNP West)) (NN combination)) (PP (IN of) (NP (NNS medicines)))) (VP (VBZ is) (ADVP (RB now)) (VP (VBN suggested) (S (VP (TO to) (VP (VB be) (NP (DT the) (VBN recommended) (NN course))))))) (. .)))
13: (ROOT (S (PP (IN With) (NP (NP (DT the) (NN advent)) (PP (IN of) (NP (DT an) (VBG ageing) (NN society))))) (, ,) (NP (NP (JJ many) (NNS studies)) (PP (IN in) (NP (DT the) (JJ past) (CD ten) (NNS years)))) (VP (VBP have) (VP (VBN shown) (SBAR (IN that) (S (NP (NNS mitochondria)) (VP (VBP are) (ADJP (RB closely) (VBN related) (PP (IN to) (NP (NP (NN ageing)) (CC and) (NP (JJ degenerative) (NNS diseases)))))))))) (. .)))
14: (ROOT (S (NP (DT This)) (VP (VBZ is) (SBAR (IN because) (S (SBAR (WHADVP (WRB when)) (S (NP (JJ mitochondrial) (NN function)) (VP (VBZ is) (ADJP (JJ abnormal))))) (, ,) (NP (PRP it)) (VP (MD will) (VP (VP (VB trigger) (NP (NP (DT a) (NN lack)) (PP (IN of) (NP (NP (NN energy) (NN supply)) (CC and) (NP (JJ oxidative) (NN stress)))))) (, ,) (CC and) (ADVP (RB even)) (VP (VB induce) (NP (NNS cells)) (S (VP (TO to) (VP (VB enter) (NP (NP (NP (NN apoptosis)) (CC or) (NP (NN autophagy))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD will) (VP (VB cause) (NP (NN disease)))))))))))))))) (. .)))
15: (ROOT (S (NP (NNP MAB)) (ADVP (RB also)) (VP (VP (VBZ establishes) (NP (NP (DT a) (NN series)) (PP (PP (IN of) (NP (NML (NN training) (CC and) (NN certification)) (NNS mechanisms))) (PP (IN for) (NP (JJ medical) (NNS personnel)))))) (CC and) (VP (VBZ cooperates) (PP (IN with) (NP (NP (NP (JJ medical) (NNS institutions)) (CC and) (NP (JJ academic) (NNS institutions))) (PP (IN around) (NP (DT the) (NN world))))))) (. .)))
16: (ROOT (S (NP (DT This)) (VP (VBZ makes) (S (NP (PRP it)) (NP (NP (DT a) (JJ prime) (NN candidate)) (PP (IN for) (NP (NP (NN impact) (VBG investing)) (PP (IN towards) (NP (NN sustainability) (NN development))) (, ,) (PP (IN in) (NP (NP (NN alignment)) (PP (IN with) (NP (NP (DT the) (NNP United) (NNPS Nations)) (CC and) (NP (PRP$ its) (CD 17) (NML (NNP Sustainable) (NNP Development)) (NNPS Goals))))))))))) (. .)))
17: (ROOT (S (NP (NP (DT The) (NNP Company)) (PP (IN along) (PP (IN with) (NP (NP (JJ other) (NN biotech) (NNS companies)) (PP (IN in) (NP (DT the) (NN field))))))) (VP (VBP have) (VP (VBN developed) (NP (NP (JJ many) (NN product) (NNS lines)) (, ,) (PP (VBG including) (NP (NP (ADJP (JJ mitochondrial) (VBN activated)) (NN stem) (NNS cells)) (, ,) (NP (JJ mitochondrial) (NNS biologics)) (, ,) (NP (JJ mitochondrial) (VBN activated) (JJ immune) (NNS cells)) (, ,) (NP (NML (JJ mitochondrial) (NN function)) (NNS tests)) (, ,) (NP (JJ mitochondrial) (JJ aesthetic) (NN medicine)) (, ,) (NP (NML (JJ mitochondrial) (NN cell)) (NN bank)) (, ,) (NP (NP (NNS mitochondria) (JJ activated) (JJ herbal) (NNS extracts)) (, ,) (NP (NNS mitochondria) (JJ activated) (NN health) (NN food))) (, ,) (NP (NNS mitochondria) (NN activation) (NN culture) (NN medium)) (, ,) (FW et) (. .)))))) (, ,)))
18: (ROOT (S (NP (JJ Other) (NNS products)) (VP (VBP are) (ADVP (RB cooperatively)) (VP (VBN sold) (PP (IN in) (NP (NP (DT the) (NNS fields)) (PP (IN of) (NP (NP (JJ preventive) (NN health) (NN care)) (, ,) (NP (JJ medical) (NN beauty)) (, ,) (NP (NN cell) (NN culture)) (, ,) (NN detection) (CC and) (NN analysis))))))) (. .)))
19: (ROOT (S (NP (DT These) (NNS products)) (VP (VBP have) (VP (VBN proven) (S (NP (NN safety) (CC and) (NN effectiveness))) (PP (IN in) (NP (JJ preliminary) (NNS studies))))) (. .)))
20: (ROOT (S (ADVP (RB Furthermore)) (, ,) (NP (NP (NNP Mitochondria)) (PP (IN for) (NP (NML (NN stem) (NN cell)) (NN therapy)))) (VP (VBZ is) (NP (NP (DT another) (NN frontier)) (PP (IN for) (NP (JJ regenerative) (NN medicine))))) (. .)))
21: (ROOT (S (S (NP (NN Stem) (NNS cells)) (VP (VBP are) (NP (ADJP (JJ primitive) (CC and) (JJ unspecialized)) (NNS cells)))) (, ,) (S (NP (PRP they)) (VP (VBP are) (NP (NP (NP (DT a) (NN type)) (PP (IN of) (NP (NNS cells)))) (SBAR (WHNP (WDT that)) (S (VP (VP (VBP are) (RB not) (ADVP (RB sufficiently)) (VBN differentiated)) (CC and) (VP (VBP have) (NP (DT the) (NN potential) (S (VP (TO to) (VP (VB regenerate) (NP (JJ various) (NNS tissues) (CC and) (NNS organs))))))))))))) (. .)))
22: (ROOT (S (PP (IN In) (NP (NN medicine))) (, ,) (NP (NN stem) (NNS cells)) (VP (VBP have) (ADVP (RB long)) (VP (VBN been) (VP (VBN considered) (S (VP (TO to) (VP (VB have) (NP (NP (NN potential)) (PP (IN for) (NP (JJ medical) (NNS applications))))))) (PP (IN because) (IN of) (NP (NP (PRP$ their) (JJ strong) (NN potential)) (PP (IN for) (S (VP (VBG treating) (NP (NP (JJ physical) (NN damage)) (VP (VBN caused) (PP (IN by) (NP (NP (NN disease)) (, ,) (NP (NN aging)) (, ,) (NP (JJ genetic) (NNS factors)) (CC or) (NP (NN trauma)))))))))))))) (. .)))
23: (ROOT (S (PP (IN In) (NP (JJ international) (NN research))) (, ,) (NP (NNS mitochondria)) (VP (VBP are) (NP (NP (DT an) (JJ important) (NN factor)) (VP (VBG affecting) (NP (NP (DT the) (NN quality)) (PP (IN of) (NP (NN stem) (NNS cells))))))) (. .)))
24: (ROOT (S (PP (IN By) (S (VP (VBG analyzing) (NP (NP (DT the) (NN function)) (PP (IN of) (NP (NNS mitochondria))) (PP (IN in) (NP (NN stem) (NNS cells)))) (PP (IN as) (NP (NP (DT a) (NN way)) (SBAR (S (VP (TO to) (VP (VB identify) (NP (NP (DT the) (NN quality)) (PP (IN of) (NP (NNS cells))))))))))))) (, ,) (NP (PRP it)) (VP (VBZ provides) (NP (NP (DT a) (JJ scientific) (NN way)) (SBAR (S (VP (TO to) (VP (VB identify) (NP (NN cell) (NN quality)))))))) (. .)))
25: (ROOT (S (NP (NP (DT The) (NN company) (POS 's)) (NN research)) (VP (VBZ is) (S (VP (TO to) (VP (VB improve) (NP (NP (DT the) (NN quality) (CC and) (NN function)) (PP (IN of) (NP (NN stem) (NNS cells)))) (PP (IN by) (S (VP (VP (VBG screening)) (CC and) (VBG increasing) (NP (JJ mitochondrial) (NN function))))))))) (. .)))
26: (ROOT (S (NP (NP (NN Stem) (NNS cells)) (VP (VBN activated) (PP (IN by) (NP (NNS mitochondria))))) (VP (VBP have) (NP (JJR better) (JJ therapeutic) (NNS effects))) (. .)))
27: (ROOT (S (NP (NP (PRP$ Our) (NN company) (POS 's)) (ADJP (JJ mitochondrial) (VBN activated)) (NN stem) (NNS cells)) (VP (VBP have) (ADVP (RB also)) (VP (VBN been) (VP (VBN proven) (S (VP (S (VP (TO to) (VP (VB be) (ADJP (JJ useful) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NP (NNP Parkinson) (POS 's)) (NN disease)) (, ,) (NP (NNP Osteoarthritis)) (, ,) (NP (NML (NNP Multiple) (NNP System)) (NNP Atrophy)))))))))) (ADVP (RB Lastly)) (, ,) (PP (IN in) (NP (NP (NN addition)) (PP (IN to) (NP (NP (DT the) (JJ aforementioned) (NNS products)) (PP (IN in) (NP (DT the) (NN market))))))) (, ,) (NP (NML (JJ mitochondrial) (NN replacement)) (NNS techniques)) (VP (VBP work) (S (VP (TO to) (VP (VB prevent) (S (VP (VBG transmitting) (NP (NML (JJ mitochondrial) (NNP DNA)) (NNS diseases)) (PP (IN from) (NP (NN mother))) (PP (IN to) (NP (DT the) (JJ next) (NN generation)))))))))))))) (. .)))
28: (ROOT (S (NP (JJ Such) (NNS diseases)) (VP (VBP vary) (PP (IN in) (NP (NN presentation) (CC and) (NN severity)))) (. .)))
29: (ROOT (S (NP (NP (DT The) (NN goal)) (PP (IN of) (NP (NNP MRT)))) (VP (VBZ is) (S (VP (TO to) (VP (VB prevent) (NP (NP (DT the) (NN transmission)) (PP (IN of) (NP (JJ such) (NNS diseases)))) (PP (IN by) (S (VP (VBG creating) (NP (DT an) (NN embryo)) (PP (IN with) (NP (NP (NP (JJ nuclear) (NN DNA)) (PP (IN from) (NP (DT the) (JJ intended) (NN mother)))) (CC and) (VP (NP (NN mtDNA)) (PP (IN from) (NP (NP (DT a) (NN woman)) (PP (IN with) (NP (ADJP (DT no) (HYPH -) (JJ pathogenic)) (NN mtDNA)))))))) (PP (IN through) (NP (NP (NN modification)) (PP (IN of) (NP (DT either) (DT an) (NN oocyte) (CC or) (NN zygote)))))))))))) (. .)))
30: (ROOT (S (NP (DT This)) (VP (MD will) (VP (VB help) (S (VP (VB alleviate) (NP (NP (NP (JJ common) (NNS symptoms)) (PP (VBG including) (NP (NP (JJ developmental) (NNS delays)) (, ,) (NP (NNS seizures)) (, ,) (NP (NN weakness) (CC and) (NN fatigue)) (, ,) (NP (NN muscle) (NN weakness)) (, ,) (NP (NN vision) (NN loss)) (, ,) (CC and) (NP (NN heart) (NNS problems))))) (, ,) (SBAR (WHNP (WDT which)) (S (PP (IN in) (NP (NN combination))) (VP (VBP lead) (PP (IN to) (NP (NP (NP (DT an) (NN increase)) (PP (IN of) (NP (NN morbidity)))) (CC and) (PP (IN in) (NP (DT some) (NNS cases))) (NP (JJ premature) (NN death)))))))))))) (. .)))
31: (ROOT (S (SBAR (IN While) (S (NP (NN research)) (VP (VBZ continues) (S (VP (TO to) (VP (VB be) (VP (VBN conducted)))))))) (, ,) (SBAR (IN if) (FRAG (ADJP (JJ effective)))) (, ,) (NP (NNP MRT)) (VP (MD could) (VP (VB satisfy) (NP (NP (DT the) (NN desire)) (PP (IN of) (NP (NP (NNS women)) (VP (VBG seeking) (S (VP (TO to) (VP (VB have) (NP (DT a) (ADJP (RB genetically) (VBN related)) (NN child)) (PP (IN without) (NP (NP (DT the) (NN risk)) (PP (IN of) (S (VP (VBG passing) (PRT (RP on)) (NP (NNP mtDNA) (NN disease)))))))))))))))) (. .)))
32: (ROOT (S (PP (IN In) (NP (NP (DT the) (NNP US)) (ADVP (RB alone)))) (, ,) (NP (JJ mitochondrial) (NNS diseases)) (VP (VBP affect) (NP (QP (RB around) (CD 1) (IN in) (CD ,) (CD 000)) (NNS individuals))) (. .)))
33: (ROOT (S (NP (PRP It)) (VP (VBZ is) (ADVP (RB also)) (VP (VP (VP (VBN estimated) (SBAR (IN that) (S (NP (QP (CD ,) (CD 00-,000)) (NNS children)) (VP (VBP are) (VP (VBN born) (PP (IN with) (NP (DT a) (JJ mitochondrial) (NN disease))) (NP (DT every) (NN year))))))) (ADVP (RB Therefore))) (, ,) (NP (EX there)) (VP (VBZ is) (NP (DT a) (JJ direct) (NN need) (S (VP (TO to) (VP (VB focus) (PP (IN on) (S (VP (VBG building) (NP (NP (DT a) (NML (NN world) (NN class)) (JJ professional) (NML (NML (JJ mitochondrial) (NN technology)) (CC and) (NML (NN manufacturing))) (NN leader)) (, ,) (PP (IN with) (NP (NP (DT a) (NN purpose)) (PP (IN in) (S (VP (VBG creating) (NP (NP (NP (JJ affordable) (NN healthcare)) (CC and) (NP (NN biotech) (NN leadership))) (PP (IN in) (NP (JJ preventative) (NN medicine)))))))))))))))))))) (. .)))
34: (ROOT (S (NP (PRP It)) (ADVP (RB also)) (VP (VBZ creates) (NP (NP (DT a) (NN space)) (SBAR (IN for) (S (NP (NP (DT the) (NN community)) (PP (IN of) (NP (NML (JJ social) (NN impact)) (NN investing)))) (VP (TO to) (VP (VB be) (ADJP (ADVP (RBR more) (RB deeply)) (VBN involved) (PP (IN in) (NP (NN health) (CC and) (NN wellbeing)))))))))) (. .)))
